ArticleInternational journal of clinical and experimental medicine2015
Neuregulin protects human umbilical vein endothelial cell via activating CD98hc through MAPK pathway.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo study the effects of neuregulin on human umbilical vein endothelial cells (HUVEC) protection.
methodsThe HUEVC were cultured and divided into three different groups according to their culture conditions. In negative control group (group A), HUVEC were cultured in dulbecco modified eagle medium (DMEM) supplemented with 25 mmol/L glucose and neuregulin (10 ng/ml, 100 ng/ml, and 1000 ng/ml, respectively) for 48 hr. In experimental group (group B), HUVEC were cultured in DMEM with 75 mmol/L glucose and neuregulin (10 ng/ml, 100 ng/ml, and 1000 ng/ml, respectively) for 48 hr. In positive control group (group C), HUVEC were cultured in DMEM supplemented with 75 mmol/L mannitol, 25 mmol/L glucose, and neuregulin (10 ng/ml, 100 ng/ml, and 1000 ng/ml, respectively) for 48 hr. This study aimed to observe the cell morphology in different HUEVC groups and analyze apoptosis in each group via characterizing and detecting the protein expressions of CD98hc, p38, and JNK.
resultsSignificant differences in cell morphology were observed in the experimental group when compared with the control groups. In the experimental group, the degree of apoptosis was negatively related to the neuregulin concentration; CD98hc protein concentration was positively related to neuregulin concentration; JNK protein concentration was positively related to neuregulin concentration. However, there was no significant relationship between p38 protein expression and the concentration of glucose in the medium.
conclusionNeuregulin could inhibit the apoptosis of HUEVC through the activation of MAPK signaling pathway via activating CD98hc expression.
Indexed as
Identifiers
26221208PMC4509153W952425133What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.